HONG KONG – The lack of cross-border regulations and coordination on genetic editing in general – and gene editing on embryos specifically – has emerged a key concern for industry leaders and regulators and a timely topic at the Second International Summit on Human Genome Editing in Hong Kong on Tuesday.